Task 4.2

Description

WP4 will help to select promising lead tracers that are generated in WP3 and immunotracers that are already available. The selection process will be based on in vivo imaging performance parameters, such as pharmacokinetics, retention, non-specific ba

WP4 will help to select promising lead tracers that are generated in WP3 and immunotracers that are already available. The selection process will be based on in vivo imaging performance parameters, such as pharmacokinetics, retention, non-specific ba...

General Design

Type: Cohort study
Start/End data collection: not available

Organisations

Lead organisations

BAYER AKTIENGESELLSCHAFT
Germany
https://www.bayer.com/en/
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
https://uni-tuebingen.de/en/
F. HOFFMANN-LA ROCHE AG
Switzerland
https://www.roche.com/
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Spain
STICHTING VUMC (P1)
Netherlands (the)
https://www.vumc.nl/
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom of Great Britain and Northern Ireland (the)
https://www.cam.ac.uk/
University Medical Centre Groningen (UMCG)
Netherlands (the)
https://www.umcg.nl/
VRIJE UNIVERSITEIT BRUSSEL
Belgium
https://www.vub.be/en/home
WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER
Germany
https://www.uni-muenster.de/en/

Networks

Part of networks

Part of networks...

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies
Website